<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Merci Retriever is a device used for mechanical clot extraction in cerebral arteries </plain></SENT>
<SENT sid="1" pm="."><plain>It obtained US FDA clearance in August 2004 for recanalization of cerebral arteries in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Previously, intravenous recombinant tissue plasminogen activator administered within 3 h from symptom <z:hpo ids='HP_0003674'>onset</z:hpo> was the only other FDA-approved treatment in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> from large brain <z:mp ids='MP_0006134'>artery occlusion</z:mp>, which has the highest morbidity and mortality rate, is inefficiently treated with intravenous recombinant tissue plasminogen activator and has a high likelihood of hemorrhagic complication </plain></SENT>
<SENT sid="4" pm="."><plain>In the multicenter prospective Mechanical <z:mpath ids='MPATH_110'>Embolus</z:mpath> Removal in <z:hpo ids='HP_0002637'>Cerebral Ischemia</z:hpo> trial that led to FDA clearance, the Merci Retriever achieved 48% vessel recanalization when used within 8 h of <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo>, and resulted in lower morbidity and mortality in revascularized patients </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical efficacy trials are needed to determine the place of this device in the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
</text></document>